












































































































































































































































Ab	 	 	 42	amino	acid	peptide	cleaved	from	APP	
AChE	 	 	 Acetylcholinesterase	
ACSF	 	 	 artificial	cerebrospinal	fluid	
AD	 	 	 Alzheimer’s	Disease	
ADDLs		 	 Amyloid-beta	derived	diffusible	ligands	
AICD	 	 	 Amyloid	precursor	protein	intracellular	domain	
AMPAR	 	 a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic	acid	receptor	
APLP	 	 	 Amyloid	precursor	like	protein	
APOE	 	 	 Apolipoprotein	E	
APP	 	 	 Amyloid	precursor	protein	
APV	 	 	 2-amino-5-phosphonopentanoic	acid	(NMDAR	antagonist)	
ATP	 	 	 Adenosine	tri-phosphate	
BACE	 	 	 Beta-secretase	1	
BDNF	 	 	 Brain-derived	neurotrophic	factor	
BSA	 	 	 Bovine	serum	albumin	
CaMKII	 	 Calcium/calmodulin-dependent	protein	kinase	II	
CaN	 	 	 Calcineurin	
	 xiv	
CDK5	 	 	 Cyclin-dependent	kinase	5	
CHO	 	 	 Chinese	hamster	ovary	
CK2	 	 	 Casein	kinase	2	
COS	 	 	 CV-1	cells	in	origin,	carrying	the	SV40	genetic	material	
CPP	 3-(2-Carboxypiperazin-4-yl)propyl-2-phosponic	acid	(NMDAR	
antagonist)	
CSF	 	 	 Cerebrospinal	fluid	
CTFa	 	 	 C-terminal	fragment	of	APP	
DAPK1	 	 Death-associated	protein	kinase	1	
DHA	 	 	 Docosahexaenoic	acid	
EphB2		 	 Ephrin	type	B	receptor	2	
ER	 	 	 Endoplasmic	reticulum	 	 	 	
FcgRIIb	 	 Low	affinity	immunoglobulin	gamma	Fc	region	receptor	II-b	
FDA	 	 	 Food	and	Drug	Administration	
GA	 	 	 Golgi	apparatus	
GFP	 	 	 Green	fluorescent	protein	
GluA1	 	 	 AMPA-type	glutamate	receptor	subunit	1	
GluN1	 	 	 NMDA-type	glutamate	receptor	subunit	1	
GluN2A	 	 NMDA-type	glutamate	receptor	subunit	2A	
GluN2B	 	 NMDA-type	glutamate	receptor	subunit	2B	




iLTD	 	 	 Inhibitory	long-term	depression	
iLTP	 	 	 Inhibitory	long-term	potentiation	
iNOS	 	 	 Inducible	nitric	oxide	synthase	
IRES	 	 	 Internal	ribosomal	entry	site	
LRP1	 	 	 Low	density	lipoprotein	receptor-related	protein	1	
LTD	 	 	 Long-term	depression	
LTP	 	 	 Long-term	potentiation	
mEPSC	 	 Miniature	excitatory	postsynaptic	current	
mGluR5	 	 Metabotropic	glutamate	receptor	5		
MNI	 	 	 4-Methoxy-7-nitroindolinyl	(caging	compound	for	glutamate)	
NADPH	 	 Nicotinamide	adenine	dinucleotide	phosphate	
NFAT	 	 	 Nuclear	factor	of	activated	T-cells	
NFkB	 	 	 Nuclear	factor	kappa-light-chain-enhance	of	activated	B	cells	
NFTs	 	 	 Neurofibrilary	tangles	of	hyperphosphorylated	tau	
NMDAR	 	 N-methyl-D-aspartate	receptor	
NO	 	 	 Nitric	oxide	
PALM	 	 	 Photoactivated	light	microscopy	
PKA	 	 	 Protein	kinase	A	
PKC	 	 	 Protein	kinase	C	
PP1	 	 	 Protein	phosphatase	1	
PP2A	 	 	 Protein	phosphatase	2A	
PPF	 	 	 Paired-pulse	facilitation	
preNMDAR	 	 Presynaptic	NMDAR	
	 xvi	
PrPC	 	 	 Cellular	prion	protein	
PSD	 	 	 Post-synaptic	density	
PSEN1		 	 Presenilin1	
QCT	 	 	 Quantal	Calcium	Transient	
ROI	 	 	 Region	of	interest	
ROS	 	 	 Reactive	oxygen	species	
SIM	 	 	 Structured	illumination	microscopy	
SNARE	 	 Soluble	N-ethylmaleimide-sensitive	factor	activating	protein	receptor	
STED	 	 	 Stimulated	emission	depletion	microscopy	
STEP61	 	 Striatal-enriched	protein	tyrosine	phosphatase	 	
STORM	 	 Stochastic	optical	reconstruction	microscopy	
TBOA	 	 	 DL-threo-beta-benzyloxyaspartate	(glutamate	reuptake	inhibitor)	
TeNT	 	 	 Tetanus	toxin	light	chain	
TNFa	 	 	 Tumor	necrosis	factor	alpha	
TrkB	 	 	 Tropomyosin	receptor	kinase	B	
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































STED image analysis will be performed using the same algorithms as the SIM data, but 
in two dimensions instead of three. Qualitatively, Ab appears to localize near the PSD95 
staining, typically surrounding it, with very little direct overlap between the two (Figure 5-5).  
A similar distribution is seen in the PALM/STORM data using PSD95ib-mEos3.2 to 
mark synapses and HiLyte647 dye directly conjugated to Ab (Figure 5-6). Analysis of 
PALM/STORM and 2-color STORM will be performed similarly to the PALM/STORM analysis 
previously performed in our lab331. Briefly, the	coordinates	of	single-molecule	events	are	
obtained	by	fitting	a	2D-Gaussian	function	to	intensity-peaks	in	individual	frames	and	
single-molecule	peaks	with	overlapping	fitting	windows	are	discarded.	Data	is	then	drift-
corrected	using	a	model-based	algorithm	in	Zen	(Zeiss,	proprietary).	Fidelity	of	the	drift-
correction	is	confirmed	by	visual	inspection	of	the	localizations	for	the	TetraSpeck	fiducial	
markers.	Only	localizations	with	an	estimated	precision332,333	of	10-50nm	are	used	in	
subsequent	analyses.		
Localization	data	are	imported	into	MATLAB	(MathWorks)	where	localizations	are	
overlapped	and	registered	with	a	widefield	image	of	the	488	channel	acquired	before	
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imaging.	Regions	of	interest	(ROI)	are	drawn	around	individual	dendritic	spines	and	
localizations	within	the	ROI	are	saved	for	further	analysis.	Density-based	cluster	analysis	
(DBSCAN) 334	implementation	in	the	PALMsiever	platform335	is	used	to	define	core,	
clustered	PSD95	localizations.	The	criterion	for	assigning	individual	localizations	as	core	
PSD	points	is	the	presence	of	a	minimum	of	25	neighboring	localizations	within	a	100	nm	
radius.	We	found	these	parameters	were	robust	in	identifying	PSD95	clusters	consistent	
with	the	size	and	shape	previously	described	in	the	literature336,337.	The	delimitation	of	the	
boundaries	of	the	PSD95	cluster	are	determined	by	using	a	MATLAB	boundary	function	on	
the	points	assigned	a	core	designation	(Figure	5B).	We	can	then	measure	the	amount	of	Ab	
within	vs.	outside	the	PSD,	similar	to	the	GluA1/PSD95	overlap	shown	in	Figure	5-6C.	We	
can	also	perform	the	same	DBSCAN	cluster	analysis	on	the	Ab	and	determine	the	average	
distance	from	the	center	of	the	Ab	clusters	to	their	nearest	PSD95	cluster	and	the	average	
number	of	clusters	within	varying	distances	from	the	center	of	the	PSD95	objects.		
Discussion	
	 This	is	the	first	quantitative	analysis	of	Ab	binding	relative	to	a	variety	of	synaptic	
markers.	While	other	groups	have	observed	Ab	(endogenous	and	exogenous)	binding	
relative	to	synaptic	markers,	our	detailed	quantification	of	the	location	of	Ab	binding	
provides	additional	insight	into	Ab	localization	and	maybe	help	narrow	down	the	number	
of	potential	Ab	receptors.	Super	resolution	imaging	is	also	a	straightforward	way	to	
observe	Ab	binding	relative	to	these	proposed	receptors	and	confirm	colocalization	or	
biochemical	interaction	assays.		
	 We	chose	to	use	three	separate	super	resolution	techniques	to	quantify	Ab	binding	
at	synapses.	SIM	provides	the	ability	to	image	synapses	in	three	dimensions	and	also	allows		
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Figure	5-5.	STED	imaging	of	Ab	and	PSD95	
Example	images	of	individual	excitatory	synapses	stained	for	PSD95	(red;	STAR635p)	and	
Ab	(green;	STAR594).	
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Figure	5-6.	PALM/STORM	imaging	of	PSD95	and	Ab	
A.	Individual	excitatory	synapses	from	cells	expressing	PSD95ib-mEos3.2	(cyan)	and	
labeled	with	HiLyte647-Ab	(magenta).	
B.	Example	image	of	GluA1	(cyan)	and	PSD95	(magenta)	PALM/STORM	localizations	
aligned	with	widefield	GFP	to	mark	the	cell	using	VividSTORM.		
C.	Two	example	images	of	PSD95	DBSCAN	clustering	followed	by	segmentation	of	GluA1	
within	(blue)	vs.	outside	(cyan)	the	PSD95	cluster	area	(marked	in	red).		 	
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us	to	orient	our	synapses	based	on	pre	and	post	synaptic	markers	since	we	can	use	three	
color	imaging	of	conventional	dyes.	The	limitation	of	SIM	is	the	resolution	is	not	as	high	as	
STED	or	STORM.	Thus,	we	further	observed	and	have	plans	to	quantify	Ab	binding	relative	
to	PSD95	using	these	techniques	and	will	also	characterize	binding	of	Ab	relative	to	
presynaptic	markers	such	as	bassoon	or	synapsin	using	two	color	STORM	in	the	future.	We	
also	plan	to	perform	electron	microscopy	in	order	to	further	confirm	post	synaptic	binding.		
Based	on	our	observations	using	all	three	techniques	Ab	appears	to	bind	to	a	
receptor	that	is	extrasynaptic	to	PSD95.	We	do	not	see	high	levels	of	colocalization	with	
NR1,	surface	GluA1	or	APP	using	SIM,	suggesting	that	these	proteins	are	not	direct	
receptors	of	Ab	even	though	NMDARs	and	AMPARs	are	downstream	targets	of	Ab	binding.	
Future	work	will	focus	on	other	proposed	receptors,	including	mGluR5,	PirB	and	PrPC,	
however	these	will	require	additional	work	since	antibodies	against	these	targets	need	
troubleshooting.	Further	analysis	of	the	SIM,	STED	and	PALM/STORM	images	may	provide	
additional	information	about	the	pattern	of	Ab	binding.		
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CHAPTER	VI	
LOCAL	AND	USE-DEPENDENT	EFFECTS	OF	Ab	OLIGOMERS	REVEALED	BY	OPTICAL	
QUANTAL	ANALYSIS2	
Introduction	
Widely	recognized	as	one	of	the	primary	pathological	agents	responsible	for	
Alzheimer’s	disease	(AD),	β-amyloid	peptide	triggers	a	broad	host	of	cellular	pathologies	
including	synapse	loss,	tau	phosphorylation,	and	ultimately	cell	death	57,75,76,133,134,146,249.	
One	of	the	earliest	manifestations	of	AD	in	the	central	nervous	system	is	the	loss	of	
excitatory	synapses	and	impaired	function	at	remaining	synapses,	which	precedes	
widespread	neuronal	cell	death	338,339.	
Accumulating	evidence	suggests	that	early	synaptic	dysfunction	is	triggered	by	
soluble	oligomeric	assemblies	of	the	42	amino	acid	Aβ	peptide	(Aβo),	which	binds	to	the	
surface	of	neurons	and	forms	clusters	in	close	proximity	to	a	large	fraction	of	excitatory	
synaptic	sites	74,94,340.	Acute	exposure	to	nanomolar	concentrations	of	Aβo	blocks	
fundamental	forms	of	synaptic	plasticity,	including	long	term	potentiation	(LTP),	within	
minutes	and	triggers	depression	and	eventual	elimination	of	excitatory	synaptic	
connections	over	the	course	of	days	57,71,72,145-147,341.	Intriguingly,	a	number	of	studies	have	
demonstrated	that	Aβo	synaptotoxicity	is	mediated	by	N-methyl	D-aspartate	(NMDA)	
receptors,	which	are	required	for	LTP	and	play	a	central	role	in	learning	and	memory.	
NMDA	receptor	activity	is	required	for	Aβo-induced	spine	loss	77,133	and	for	Aβo-induced	
synaptic	depression	342	but	how	Aβo	influences	NMDA	receptor	function	remains	
																																																								
2	Portions	of	this	chapter	were	previously	published	in	the	Journal	of	Neuroscience.	Reprinted	with	
permission	from	the	Society	for	Neuroscience.	Copyright	©	2018	Society	for	Neuroscience.	1	
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controversial.	Some	studies	suggest	that	Aβo	causes	a	gain	of	receptor	function	and	
disruption	of	Ca2+	homeostasis	343-345,	while	others	provide	evidence	for	loss	of	NMDA	
receptor	function	by	removal	from	the	cell	surface	and	activation	of	synaptic	depression	
signaling	pathways	70,71,133,142,147,342.	Whether	Aβo	triggers	loss	or	gain	of	NMDA	receptor	
function,	whether	Aβo	acts	locally	where	it	is	bound	to	influence	NMDA	receptor	function,	
and	whether	synaptic	activity	influences	Aβo	synaptic	binding	or	its	effects	on	NMDA	
receptor	function,	remain	fundamental	questions.		
Here	we	used	subcellular	Ca2+	imaging	to	visualize	quantal	NMDA	receptor	
responses	at	the	same	synaptic	sites	before	and	after	exposure	to	Aβo	allowing	us	to	make	
longitudinal	comparisons	of	NMDA	receptor	function	before	and	after	Aβo	exposure,	at	
thousands	of	synapses	while	simultaneously	visualizing	Aβo	localization.	Thus,	for	the	first	
time,	we	can	measure	the	relationship	between	Aβo	surface	binding,	NMDA	receptor	
function	and	activity	at	individual	synapses.	Sub-nanomolar	concentrations	of	Aβo	
triggered	a	reduction	in	synaptic	NMDA	receptor-mediated	Ca2+	entry	within	minutes	but	
had	no	effect	on	AMPA	receptor	function	over	the	same	timescale.	Surprisingly,	NMDA	
receptor	Ca2+	influx	was	impaired	at	Aβo	doses	at	least	an	order	of	magnitude	lower	than	
those	required	for	triggering	NMDA	receptor	internalization.	NMDA	receptors	were	more	
robustly	impaired	at	Aβo-bound	synapses	than	adjacent	unbound	synapses,	demonstrating	
that	Aβo	engages	local	signaling	pathways	to	disrupt	NMDA	receptor	function.	Finally,	
using	a	synapse-specific	silencing	strategy,	we	show	that	Aβo	bound	to	and	clustered	at	
excitatory	synaptic	sites	regardless	of	their	activity	state.	However,	Aβo-induced	NMDA	
receptor	impairment	required	activation	of	NMDA	receptors	through	a	mechanism	distinct	
from	receptor	internalization.		
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Materials	and	Methods	
Cell	culture	
Primary	hippocampal	neurons	were	prepared	from	neonatal	Sprague-Dawley	rats	of	
either	sex.	Hippocampi	were	dissected	from	the	brains	of	postnatal	day	0–2	rats	and	
dissociated	by	papain	digestion.	Neurons	were	plated	at	150,000-175,000	cells/dish	in	
MEM,	10%	FBS	(Hyclone)	containing	penicillin/streptomycin	on	poly-d-lysine–coated	35	
mm	glass	bottom	dishes.	After	1	day	the	media	was	replaced	with	Neurobasal-A	
supplemented	with	B27	(Invitrogen)	and	GlutaMAX	(ThermoFischer).	The	neurons	were	
then	fed	with	Neurobasal-A,	B27,	and	mitotic	inhibitors	(uridine	+	fluoro-deoxyuridine	
[Ur+FdUr])	by	replacing	half	the	media	on	day	6	or	day	7	and	then	once	weekly.	Neurons	
were	maintained	at	37°C	in	a	humidified	incubator	at	5%	CO2.	Neurons	were	transfected	
using	Lipofectamine	2000	(Invitrogen)	according	to	the	manufacturer’s	recommendations	
and	allowed	to	express	for	48	hours.	For	all	Ca2+	imaging	experiments,	neurons	were	
transfected	with	a	plasmid	encoding	the	genetically	encoded	Ca2+	indicator	GCaMP6s	346	
(Addgene	plasmid	#40753).	All	neurons	were	between	DIV16	and	DIV19	at	the	time	of	
experiment.			
Aβ	preparation	
	 HiLyte	Fluor	647	and	555-labeled	Aβ1-42	(AnaSpec)	were	prepared	(using	a	ratio	of	
1:3	labeled:unlabeled)	in	aliquots	as	a	dried	1,1,1,3,3,3-hexafluoro-2-propanol	film	and	
stored	at	-80°C	a	previously	described	328.	The	peptide	film	was	dissolved	in	4.4	μL	
anhydrous	DMSO	and	diluted	to	50	μM	with	1x	PBS	and	allowed	to	oligomerize	at	4°C	
overnight.	The	preparation	was	centrifuged	at	14,000	X	g	for	10	min	at	4°C	to	remove	
insoluble	aggregates.	The	supernatants	were	then	filtered	using	a	30	kDa	cut-off	Microcon	
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YM-30	filter	(Millipore).	The	flow	through	was	discarded	and	the	peptide	remaining	on	the	
filter	was	resuspended	in	600	μL	PBS	(10	μM)	and	kept	on	ice	until	use.	Scrambled	Aβ	
peptide	(AnaSpec)	was	prepared	in	the	same	manner,	skipping	the	size	exclusion	filter	step	
as	they	do	not	multimerize.	Since	these	Aβ	preparations	are	highly	heterogeneous,	it	is	
likely	that	the	concentration	of	the	oligomeric	Aβ	species	is	actually	lower	than	what	is	
reported	in	our	dose-response	curves,	which	were	calculated	assuming	complete	
incorporation	of	Aβ	peptide	into	oligomers	and	without	accounting	for	peptide	that	was	
removed	in	the	insoluble	fraction.	
Pharmacological	reagents	
	 DL-AP5	(Tocris,	50	µM)	and	Mg2+	(Sigma,	1	mM)	were	used	to	inhibit	NMDA	
receptors.		TTX	(Tocris,	2	µM)	was	used	to	inhibit	voltage-gated	sodium	channels.	
Ifenprodil	(Tocris,	5	µM)	was	used	to	inhibit	GluN2B-containing	NMDARs.	
Live	cell	imaging	
	 Live	cell	imaging	of	dissociated	neurons	was	carried	out	at	34°C	on	an	Olympus	IX71	
equipped	with	a	spinning	disc	scan	head	(Yokogawa).	Excitation	illumination	was	delivered	
from	an	acousto-optic	tunable	filter	(AOTF)	controlled	laser	launch	(Andor).	Images	were	
acquired	using	a	60x	Plan	Apochromat	1.4	NA	objective,	and	collected	on	a	1024x1024	
pixel	Andor	iXon	EM-CCD	camera.	Data	acquisition	and	analysis	were	performed	with	
Metamorph	(Molecular	Devices)	and	ImageJ	software.		
Ca2+	imaging	and	analysis	
	 To	image	QCTs,	neurons	transfected	with	GCaMP6(s)	were	incubated	in	an	artificial	
cerebro-spinal	fluid	(ASCF)	solution	containing	(in	mM):	130	NaCl,	5	KCl,	10	HEPES,	30	
glucose,	2.5	CaCl2,	and	0.002	TTX	(pH	7.4)	347.	Single	z-plane	images	of	a	portion	of	the	
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dendritic	arbor	were	acquired	at	7	Hz	for	1	min	to	record	baseline	QCTs.	500	nM	Aβ,	500	
nM	scrambled	Aβ	peptide	or	PBS	was	added	directly	and	cells	were	incubated	for	45	min.	
The	same	z	plane	was	then	imaged	again	to	record	QCTs	post	treatment.		
To	measure	the	frequency	and	amplitude	of	QCTs,	regions	of	interest	(ROIs)	were	
drawn	around	12	clearly	resolved	spines	per	cell	in	the	baseline	movie.	The	ROIs	were	
saved	and	the	same	synapses	were	analyzed	in	the	post	treatment	movie.	The	mean	
background-subtracted	GCaMP6	fluorescence	within	each	ROI	was	measured.	A	baseline	of	
10	frames	was	established	and	each	frame	was	compared	to	that	baseline.	A	threshold	of	a	
100%	increase	in	fluorescence	over	baseline	was	established	to	remove	small	variations	in	
fluorescence.	Event	frequency	and	average	amplitude	were	compared	between	baseline	
and	post-Aβo	treatment.	Data	are	plotted	as	the	change	in	frequency	or	amplitude	relative	
to	the	baseline	values.	
	 For	experiments	performed	with	Mg2+	or	APV,	baseline	QCTs	were	imaged	in	
Mg2+/APV-free	media.	Mg2+	or	APV	were	then	co-applied	with	Aβ	or	PBS	and	incubated	for	
45	min.	Inhibitors	were	then	removed	by	washing	with	ACSF	lacking	Mg2+	and	post-
treatment	QCTs	were	imaged.	Aβ	controls	(using	media	lacking	APV/Mg2+)	in	these	
experiments	were	performed	to	ensure	efficacy	of	the	Aβ	preparation.	
	 For	experiments	testing	the	effect	of	Aβo	on	NMDA	receptor	function	using	
spontaneous	network	activity	to	drive	NMDA	receptors	in	the	presence	of	Mg2+,	QCTs	were	
first	imaged	(in	2	µM	TTX/Mg2+-free	media),	followed	by	exposure	to	500	nM	Aβo	in	media	
lacking	TTX	and	containing	1	mM	Mg2+.	Following	a	60	minute	incubation,	cells	were	
returned	to	media	lacking	Mg2+	and	containing	2	µM	TTX	for	a	second	round	of	QCT	
imaging.	
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	 For	experiments	performed	with	ifenprodil,	baseline	QCTs	were	imaged.	5	µM	
ifenprodil	was	added	and	cells	were	imaged	immediately.	Next,	500	nM	Aβ	was	applied	and	
allowed	to	incubate	for	45	min,	followed	by	a	third	round	of	QCT	imaging	in	the	continued	
presence	of	5	µM	ifenprodil.	
Glutamate	uncaging	
	 For	experiments	involving	glutamate	uncaging,	neurons	were	incubated	in	artificial	
cerebro-spinal	fluid	(ASCF)	solution	containing	(in	mM):	130	NaCl,	5	KCl,	10	HEPES,	30	
glucose,	2.5	CaCl2,	and	0.002	TTX	(pH	7.4),	supplemented	with	1	mM	4-methoxy-7-
nitroindolinyl	(MNI)-caged	L-glutamate	(Tocris).	Individual	dendritic	spines	were	focally	
stimulated	using	galvanometric	mirrors	(FRAPPA,	Andor	Technologies)	to	steer	a	
diffraction-limited	405	nm	spot.	An	AOTF	was	used	to	gate	a	500	µsec	pulse	of	405	nm	
light,	with	the	laser	intensity	adjusted	to	3%	of	total	laser	power	from	a	100	mW	405	nm	
laser	that	was	fiber	coupled	to	the	FRAPPA	laser	scanning	unit.	This	protocol	reliably	
triggered	NMDA	receptor-mediated	Ca2+	transients	with	similar	amplitude	and	duration	as	
spontaneous	NMDA	receptor	activation	by	quantal	release	of	glutamate.	
Electrophysiology	
	 Dissociated	hippocampal	neurons	were	either	treated	with	Aβo	or	scrambled	
control	peptide	under	conditions	identical	as	those	used	for	QCT	imaging.	Immediately	
prior	to	recording	mEPSCs,	cells	were	switched	to	media	containing	Mg2+	and	bicuculline.	
Whole	cell	voltage	clamp	recordings	were	carried	out	from	dissociated	hippocampal	
neurons	(DIV	17-19)	bathed	in	(mM):	10	HEPES,	130	NaCl,	5	KCl,	30	d-glucose,	2	CaCl2	and	
1	MgCl2	supplemented	with	1	µM	TTX	and	30	µM	bicuculline.	Intracellular	solution	
contained	(in	mM):	130	cesium	methanesulfonate,	3	Na2ATP,	0.5	Na3GTP,	0.5	EGTA,	10	
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phosphocreatine,	5	MgCl2,	2.5	NaCl,	10	HEPES	(290-300	mOsm).	The	pH	was	adjusted	to	
7.25	with	CsOH.	Data	were	collected	using	a	multiclamp	700b	amplifier	and	digitized	using	
a	National	Instruments	DAQ	board	at	10	KHz	and	filtered	at	2	KHz	(single	pole	Bessel	filter)	
and	collected	with	WinLTP	software	(University	of	Bristol).	Data	were	analyzed	using	
WinLTP	(University	of	Bristol),	the	NeuroMatic	package	in	IGOR	Pro	(WaveMetrics)	and	
Mini	Analysis	software	(Synaptosoft).		
Lentivirus	production	
	 Synaptophysin-GFP-IRES-TeNT	was	cloned	downstream	of	the	synaptophysin	
promoter	in	a	modified	plentilox	backbone.	Lentivirus	was	packaged	in	HEK293FT	cells	
using	standard	techniques	348.	Following	at	least	24	hours	of	transfection,	supernatant	was	
harvested,	centrifuged	at	4000xg	and	filtered	through	a	0.45	µm	syringe	filter.	Virus	was	
concentrated	by	ultracentrifugation	through	a	20%	sucrose	cushion,	resuspended	in	PBS,	
aliquoted	and	stored	at	-80˚C.		
Aβo	dual	labeling	
	 HiLyte	555-labeled	Aβ	and	HiLyte	647-labeled	Aβ	were	prepared	and	described	
above.	250	nM	555-labeled	Aβ	was	applied	to	the	media	of	cultures	and	following	a	10	
minute	incubation	250	nM	647-labeled	Aβ	was	applied	to	the	same	cultures.	Following	
another	10	minute	incubation,	cultures	were	rinsed	with	ACSF	and	imaged.	The	inverse	
experiment	was	performed	in	parallel	(647-labeled	Aβ	followed	by	555-labeled	Aβ)	and	
imaged	using	the	same	imaging	parameters.	For	the	overall	binding	analysis,	a	mask	was	
drawn	around	the	neuron	using	the	GFP	cell	fill	in	ImageJ	and	the	average	561	and	647	
fluorescence	intensities	were	measured.	For	synapse	specific	binding,	ROIs	were	drawn	
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around	all	spines	(identified	using	the	GFP	cell	fill)	on	a	neuron	and	Aβ	fluorescence	levels	
were	measured.	
Surface	biotinylation	assay	
	 Surface	biotinylation	assay	was	performed	as	previously	described	with	minor	
modifications	349.	Briefly,	neurons	were	treated	in	the	same	conditions	as	used	for	imaging.	
Following	Aβo	treatment,	neurons	were	washed	3	times	in	ACSF	with	2	mM	Ca2+/1	mM	
Mg2+/1µM	TTX.	Neurons	were	then	incubated	in	ACSF	containing	1	mg/ml	EZ-link-sulfo-
NHS-LC-biotin	(Thermo)	for	10	min	at	RT.	Neurons	were	rinsed	3	times	in	ACSF	+	0.1%	
BSA	and	then	scraped	and	lysed	in	200	µl	warm	precipitation	buffer	(PB)	containing	(in	
mM):	10	NaPO4,	pH	7.4,	5	EDTA,	5	EGTA	100	NaCl,	1	Na3VO4,	10	sodium	pyrophosphate,	50	
NaF)	containing	cOmplete	ULTRA	protease	inhibitor	cocktail	tablets	(Roche),	1%	SDS	and	
1%	Triton	X-100.Lysates	were	sonicated	and	centrifuged	for	20	min	at	14,000	rpm.	Prior	to	
pull-down	of	biotinylated	proteins,	10%	of	the	cell	lysate	was	reserved	for	total	input	
quantification.	The	remaining	sample	was	combined	with	NeutrAvidin	agarose	beads	(30	
µl;	Thermo)	and	incubated	overnight	at	4ºC.	The	beads	were	washed	2	times	each	with	PB	
containing	0.1%	Triton	X-100,	0.1%	Triton	X-100	plus	600	mM	NaCl,	and	PB	alone.	To	elute	
captured	proteins,	1x	SDS-PAGE	buffer	was	added	to	the	beads	and	the	samples	were	
boiled	for	5	min	prior	to	loading	onto	10%	SDS-PAGE	gels.	Immunoblotting	was	carried	out	
with	GluN1	antibody	(1:1000	Millipore	#AB9864)	and	HRP-conjugated	secondary	antibody	
(Biorad).	Blots	were	quantified	by	comparing	the	ratio	of	biotinylated	GluN1	to	total	GluN1	
for	a	given	sample.	Values	were	normalized	to	control	samples	treated	in	an	identical	
manner,	but	not	exposed	to	Aβo.				
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Statistical	analysis	
	 Statistical	significance	for	experiments	comparing	two	populations	was	determined	
using	a	two-tailed	unpaired	Student's	t-test.	In	cases	where	the	two	populations	
represented	paired	measurements	(e.g.	pre-	and	post-	Aβo	treatment),	a	paired	Student’s	t-
test	was	used.	For	experiments	comparing	three	or	more	populations,	a	One-way	ANOVA	
with	Bonferroni	multiple	comparison	test	was	used.	All	statistical	analyses	were	performed	
using	Graphpad	Prism	(Graphpad	Software,	Inc.).	All	data	are	presented	as	mean	+/-	SEM	
unless	otherwise	noted.	
Results	
Quantal	Ca2+	transients	as	an	assay	for	synaptic	NMDA	receptor	function		
	 To	investigate	the	spatiotemporal	effects	of	Aβo	on	NMDA	receptor	function	at	
individual	synapses,	we	needed	an	assay	that	would	allow	us	to	simultaneously	interrogate	
NMDA	receptor	function	and	Aβo	binding	with	high	spatial	resolution.	Ideally,	we	would	be	
able	to	measure	NMDA	receptor	function	before	and	at	various	times	after	Aβo	exposure	at	
the	same	synaptic	sites.		Previous	reports	have	demonstrated	that	fluorescent	Ca2+	
indicators	can	be	used	to	visualize	Ca2+	influx	through	NMDA	receptors	in	response	to	
spontaneous,	quantal	neurotransmitter	release	347,350.	When	we	imaged	dissociated	
hippocampal	neurons	expressing	GCaMP6s	in	extracellular	solution	containing	
tetrodotoxin	(TTX)	to	block	evoked	neurotransmitter	release	and	nominally	Mg2+-free	
media	to	relieve	NMDA	receptor	pore	block,	we	observed	brief,	but	very	robust	
spontaneous	fluorescent	transients	that	originated	in	dendritic	spines,	the	major	sites	of	
excitatory	synaptic	contact	(Figure	6-1A).	These	events	decayed	with	a	time	constant	t	=	
0.712	+/-	0.05	sec	(Fig.	6-1A),	similar	to	the	reported	rate	of	Ca2+	dissociation	for	
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GCaMP6s346.	We	observed	a	broad	range	of	event	frequencies	at	individual	synaptic	sites,	
ranging	from	0-40	events/minute,	with	54	±	3.2%	of	dendritic	spines	exhibiting	at	least	1	
event/min.	At	the	same	synaptic	sites,	event	frequencies	were	relatively	stable	for	at	least	
60	min	(0.92	±	0.08	relative	to	baseline).	Event	amplitudes	varied	widely	from	synapse	to	
synapse,	but	multiple	events	at	the	same	synapse	displayed	amplitudes	that	were	normally	
distributed	around	the	mean	value	for	that	synapse	(p>0.1,	Kolmogorov-Smirnov	
Normality	Test),	consistent	with	single	neurotransmitter	vesicle	release	events	triggering	
postsynaptic	Ca2+	influx	(Fig.	6-1B).	These	events	were	only	observed	when	cells	were	
bathed	in	media	lacking	Mg2+(data	not	shown)	and	were	robustly	blocked	by	APV	(50	µM)	
confirming	they	originate	from	NMDA	receptor	activation	(Fig.	6-1C).	Spontaneous	Ca2+	
transients	were	within	the	dynamic	range	of	GCaMP6s	since	event	amplitudes	
approximately	doubled	(1.9	±	0.1	fold)	in	size	when	we	increased	the	concentration	of	
extracellular	Ca2+	from	2	mM	to	4	mM	(Fig.	6-1D).	We	subsequently	refer	to	these	events	as	
Quantal	Ca2+	Transients	(QCTs).		
Aβo	rapidly	reduces	synaptic	NMDA	receptor	function		
	 We	next	measured	QCTs	at	the	same	synaptic	sites	before	and	45	min	following	
application	of	500	nM	Aβo	(Fig.	6-2A).	We	observed	heterogeneous	effects	at	individual	
synapses,	with	some	synapses	showing	reduced	amplitude	(64.3%	of	synapses	displayed	
>10%	decrease)	and/or	frequency	(63.2%	of	synapses	displayed	>10%	decrease)	
responses	while	others	were	unaffected.	PBS	(vehicle)	or	scrambled	Aβ	peptide	had	no	
effect	on	QCTs	over	the	same	time	period,	confirming	that	decreased	QCT	parameters	are	
specific	to	Aβo	and	not	a	result	of	GCaMP6	photobleaching,	residual	peptide	
solvent/counter	ions,	or	a	decline	in	the	health	of	the	preparation	between	the	first	and		
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Figure	6-1.	Quantal	Ca2+	responses	as	an	assay	for	NMDA	receptor	function		
A.	Left:	Representative	image	series	of	a	single	spine	QCT	(top)	and	kymograph	(bottom)	
showing	three	consecutive	events	at	the	same	spine	over	a	1	minute	imaging	period.	
Scale	bar=5	seconds.	Right:	Successive	Ca2+	responses	at	the	same	synapse	display	
similar	kinetics	and	amplitudes.			
	
B.	QCT	amplitudes	are	normally	distributed	at	individual	synaptic	sites.	Displayed	is	a	
histogram	of	QCT	amplitudes	measured	at	individual	synaptic	sites	divided	by	the	mean	
values	for	each	respective	site	(n=	872	synapses	from	72	neurons).	Synapses	with	only	1	
QCT	during	the	1	min	imaging	period	were	not	included	in	the	analysis.	
	
C.	GCaMP6	traces	from	a	single	spine	before	(black)	and	after	(red)	application	of	50	μM	
APV.	The	APV	trace	is	vertically	offset	from	the	control	trace.	Frequency	of	QCTs	before		
(-APV)	and	after	addition	of	APV	(+APV)	is	plotted	to	the	right	(n=204	spines	from	17	
neurons).	Scale	bar=10	s.	
	
D.	Representative	Ca2+	transients	measured	from	the	same	spine	in	the	presence	of	2	mM	
(black)	or	4	mM	(red)	extracellular	Ca2+.	Relative	QCT	amplitude	and	frequency	values	in	
4	mM	vs	2	mM	Ca2+	are	plotted	to	the	right	(amplitude:	black,	n=244	spines	from	47	
neurons;	frequency:	grey,	n=281	spines	from	47	neurons).	
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second	round	of	GCaMP6	imaging	(Fig.	6-2B,C).	The	effects	of	Aβo	on	both	QCT	amplitude	
and	frequency	were	saturated	within	30	min	of	application	(Fig.	6-2D).		
A	reduction	in	QCT	parameters	could	be	presynaptic	in	origin,	resulting	from	
decreased	spontaneous	neurotransmitter	release	events	and/or	a	reduction	in	the	amount	
of	vesicular	neurotransmitter.	We	addressed	these	possibilities	using	two	independent	
approaches.	We	first	measured	AMPA	receptor	miniature	excitatory	postsynaptic	currents	
(mEPSCs)	using	Aβ	preparations	and	incubation	conditions	identical	to	those	used	for	QCT	
measurements.	We	reasoned	that	any	changes	in	presynaptic	release	properties	that	
reduced	QCT	frequency	and	amplitude	would	also	manifest	in	reduced	frequency	and	
amplitude	of	AMPA	receptor	mEPSCs.	While	previous	studies	have	shown	that	prolonged	
exposure	to	Aβ	over	the	course	of	many	hours	or	days	leads	to	reduced	excitatory	synapse	
number	with	a	concomitant	reduction	in	AMPA	receptor	mEPSC	frequency	and	amplitude	
133,183,	we	show	that	relatively	short-term	exposure	(45-75	min)	has	no	effect	(Fig	6-3A-C;	
amplitude:	Aβo	=	14.81	±	0.52	pA,	Scr.	Aβ	=	13.89	±	0.54	pA	or	frequency:	Aβo	=	3.38	±	0.49	
Hz,	Scr.	Aβ	=	2.92	±	0.35	Hz,	Aβo:	n=16	cells;	Scr.	Aβ:	n=15	cells).	Using	an	independent	
approach,	we	bypassed	pre-synaptic	release	mechanisms	by	directly	activating	NMDA	
receptors	using	MNI-glutamate	uncaging	133,351.	We	were	able	to	induce	Ca2+	transients	by	
glutamate	uncaging	that	were	nearly	identical	in	amplitude	and	duration	to	QCTs	evoked	
by	vesicular	neurotransmitter	release	(Fig.	6-3D).	Uncaging-induced	Ca2+	transients	were	
measured	under	baseline	conditions	and	then	again	at	the	same	synapses	45	min	following	
addition	of	Aβo	or	vehicle.	On	average,	Aβo	treatment	resulted	in	a	robust	decrease	in	
uncaging-evoked	spine	Ca2+	influx	compared	to	pre-Aβo	exposure,	although	29.8%	of	
synapses	displayed	no	significant	change,	supporting	our	previous	data	showing	that	
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NMDA	receptor	function	was	resistant	to	Aβo	at	a	fraction	of	synapses	(Fig.	6-2A).	Controls	
not	exposed	to	Aβo	showed	no	significant	reduction	over	the	same	time	period	(Aβo	
treated:	-26.60	±	4.33%	change	in	amplitude,	controls:	3.93	±	5.75%	change	in	amplitude;	
Fig.	6-3D-F).	Together,	this	set	of	experiments	provides	strong	evidence	that	the	Aβo-
triggered	reduction	in	QCT	parameters	we	observe	are	predominantly	due	to	impaired	
post-synaptic	NMDA	receptor	function,	but	do	not	rule	out	the	potential	for	additional	
presynaptic	impairment	following	longer	exposures	or	higher	Aβo	concentrations.		
Aβo-induced	impairment	of	NMDA	receptor	function	depends	on	receptor	activity	
	 Individual	synapses	displayed	a	wide	range	of	spontaneous	QCT	frequencies,	
allowing	us	to	compare	the	effects	of	Aβo	on	synapses	with	varying	levels	of	baseline	
spontaneous	activity.		Intriguingly,	we	observed	that	Aβo	elicited	a	significantly	larger	
reduction	in	QCT	frequency	at	synapses	that	initially	displayed	high	QCT	frequencies	
(greater	than	the	mean	value	of	4.25	events/min)	prior	to	Aβo	treatment	(Fig.	6-4A,	B).	We	
did	not	observe	this	phenomenon	when	cells	were	exposed	to	either	PBS	vehicle	alone	or	
scrambled	Aβ	peptide	over	the	same	time	period	(Fig.	6-4B;	Aβo	≤4	events	min-1:	-0.416	±	
0.800,	≥5	events	min-1:	-0.7247	±	0.0313,	p=0.04,	Student's	t-test).	We	performed	a	similar	
analysis	for	QCT	amplitude	by	comparing	synapses	with	baseline	responses	that	were	
larger	or	smaller	than	the	mean	amplitude	for	all	synapses.	Synapses	with	larger	initial	
amplitudes	were	more	significantly	impaired	than	synapses	with	smaller	initial	amplitudes	
(Fig.	6-4A,	B;	Aβo:	small	amplitude:	-0.0420	±	0.0472;	large	amplitude:	-0.495	±	0.0362;	
p<0.0001,	Students	t-test).	This	effect	was	even	more	pronounced	when	we	binned	the	
high	and	low-amplitude/frequency	based	on	the	upper	and	lower	quartile	of	the	
distribution	(Amp-lower	quart:	0.084±0.064,	upper	quart:	-0.56±0.041;	Freq-lower	quart:	-	
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Figure	6-2.	Aβo	reduces	QCT	amplitude	and	frequency		
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Figure	6-2.	Aβo	reduces	QCT	amplitude	and	frequency		
A.	Example	traces	from	single	synapses	(marked	by	boxes	in	image	to	the	left)	before	
(red)	and	following	45	min	treatment	with	500	nM	Aβo	(blue).	Individual	synapses	
displayed	(i)	no	change,	(ii)	reduced	amplitude	and	frequency	and	(iii)	complete	loss	of	
QCTs	following	Aβ	treatment.	
	
B.	QCT	amplitudes	were	measured	at	synaptic	sites	before	and	after	application	of	500	
nM	Aβo.	The	bar	graph	plots	the	change	in	QCT	amplitude	45	min	following	Aβo	
treatment	divided	by	the	baseline	(pre-Aβo)	value.	Synapses	with	no	QCTs	post	
treatment	were	eliminated	from	amplitude	analysis.	Left:	Effect	of	PBS	(black;	n=318	
synapses	from	34	neurons),	Scrambled	Aβ	peptide	(red;	n=358	synapses	from	36	
neurons)	or	Aβo	(blue;	n=218	synapses	from	39	neurons;	PBS	and	Scr.	Aβ	vs.	Aβo:	
p=0.001,	unpaired	Student's	t-test).	Right:	Cumulative	distribution	of	amplitudes	
measured	post	treatment	relative	to	baseline	for	spines	incubated	with	PBS	(black),	
Scrambled	Aβ	peptide	(red)	and	Aβo	(blue)	(p=0.036	comparing	Scrambled	Aβ	and	Aβo,	
K-S	test).		
	
C.	QCT	frequencies	were	measured	at	individual	synaptic	sites	before	and	after	
application	of	500	nM	Aβo.	The	bar	graph	plots	the	change	in	QCT	frequency	45	min	
following	Aβo	treatment	divided	by	the	baseline	(pre-Aβo)	value.	Left:	Effect	of	PBS	
(black;	n=404	synapses	from	34	neurons),	Scrambled	Aβ	peptide	(red;	n=431	synapses	
from	36	neurons)	and	Aβo	(blue;	n=467	synapses	from	39	neurons;	PBS	and	Scr.	Aβ	vs.	
Aβo:	p<0.0001,	Student's	t-test).	Right:	Cumulative	distribution	of	frequency	post	
treatment	relative	to	baseline	for	spines	incubated	with	PBS	(black),	Scrambled	Aβ	
peptide	(red)	and	Aβo	(blue)	(p=0.036	comparing	Scrambled	Aβ	and	Aβo,	K-S	test).	
	
D.	QCT	amplitude	(solid	lines)	and	frequency	(dashed	lines)	were	measured	10,	30	and	
60	minutes	following	exposure	to	PBS	(black)	or	Aβo	(blue).		For	amplitude	
measurements,	n=165	spines	(10	min),	170	spines	(30	min),	153	spines	(50	min)	from	
18	neurons	for	PBS,	and	n=210	spines	(10	min),	193	spines	(30	min),	184	spines	(60	
min)	from	24	neurons	for	Aβo.		For	QCT	frequency	measurements	n=216	spines	from	18	
neurons	for	all	time	points	for	PBS	and	n=288	spines	from	24	neurons	for	all	time	points	
for	Aβo.		
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Figure	6-3.	Aβo	impairs	NMDA	receptors	through	a	postsynaptic	mechanism.	
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Figure	6-3.	Aβo	impairs	NMDA	receptors	through	a	postsynaptic	mechanism.	
A.	Sample	traces	of	AMPA	receptor	mEPSCs	from	neurons	incubated	with	scrambled	Aβ	
peptide	or	Aβo.	Scale	bars:	20	pA	(y	axis)	and	1	second	(x	axis).	
	
B.	Left:	Average	mEPSC	frequency	following	45-75	minute	incubation	with	scrambled	Aβ	
peptide	(red;	n=15	neurons)	or	Aβo	(blue;	n=16	neurons).	Right:	Cumulative	probability	
of	inter-event	interval	for	mEPSCs.	
	
C.	Left:	Average	mEPSC	amplitude	following	45-75	minute	incubation	with	scrambled	Aβ	
peptide	(red;	n=15	neurons)	or	Aβo	(blue;	n=16	neurons).	Right:	Cumulative	probability	
of	amplitudes	with	scrambled	Aβ	(red)	or	Aβo	(blue).	
	
D.	MNI-glutamate	uncaging	Ca2+	transients	closely	resemble	spontaneous	QCTs	(left	
panel	and	kymographs).	The	right	two	panels	display	the	same	spine	before	and	after	
Aβo	treatment,	with	corresponding	uncaging-evoked	Ca2+	responses	below.	Asterisks	
denote	the	location	of	the	uncaging	spot.	Scale	bars=1	second.	
	
E.	Left:	Averaged	normalized	uncaging-evoked	spine	Ca2+	transients	measured	pre	(red	
line)	and	45	min	post	(blue	line)	treatment	with	PBS	(left;	n=36	spines	from	6	randomly	
selected	neurons)	or	Aβo	(right;	n=36	spines	from	6	randomly	selected	neurons).	Right:	
Box	and	whisker	plot	showing	the	amplitude	of	uncaging	responses	post	treatment	with	
PBS	or	Aβo	normalized	to	the	baseline	response.	Box	displays	the	median	and	upper	and	
lower	quartiles	and	whiskers	display	minimum	and	maximum	values	(PBS:	n=118	spines	
from	20	neurons;	Aβo:	n=118	spines	from	20	neurons;	p<0.0001,	Student's	t-test).		
	
F.	Left:	Average	effect	of	PBS	(black;	n=118	spines	from	20	neurons)	or	Aβo	(blue;	n=118	
spines	from	20	neurons)	on	uncaging-evoked	Ca2+	transient	amplitudes	(p<0.0001,	
Student's	t-test).	Right:	Cumulative	probability	of	the	change	in	amplitude	for	PBS	(black)	
or	Aβo-treated	cells	(blue).	
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0.315±0.081,	upper	quart:-0.79±0.037).	This	phenomenon	was	not	observed	when	cells	
were	exposed	to	scrambled	Aβ	peptide,	or	PBS	alone.	We	also	separately	analyzed	synapses	
that	had	high	initial	frequency/low	amplitude,	and	high	initial	amplitude/low	frequency	
responses.	These	synapses	also	displayed	significant	reductions	in	both	frequency	and	
amplitude	(high	amp/low	freq-Amp:	-0.51±0.046,	Freq:	-0.42±0.085;	low	amp/high	freq-
Amp:	-0.13±0.073,	Freq:	-0.73±0.037).	These	analyses	indicate	that	the	effect	of	Aβo	on	
NMDA	receptors	manifests	both	in	response	to	low,	persistent	Ca2+	influx	(i.e.	low	
amplitude,	more	frequent	QCTs)	or	high,	but	sparse	Ca2+	influx	(i.e.	large	amplitude,	less	
frequent	QCTs).	
	 While	these	data	are	correlative	in	nature,	they	suggest	that	Aβo	impairs	NMDA	
receptor	function	in	a	use-dependent	manner.	To	test	this	more	directly,	we	measured	
baseline	QCTs	and	then	inhibited	NMDA	receptors	either	by	including	Mg2+	(1	mM)	in	the	
extracellular	solution	to	block	the	receptor	pore	(but	still	allow	glutamate	binding),	or	by	
adding	the	competitive	inhibitor	APV	(50	µM)	during	Aβo	exposure.	As	in	previous	
experiments,	TTX	(2	µM)	was	also	present.	After	45	min,	APV	or	Mg2+	was	washed	out	and	
we	performed	a	second	round	of	QCT	imaging.	Both	Mg2+	and	APV	completely	prevented	
Aβo-induced	reduction	in	QCT	frequency	and	amplitude	compared	to	control	cells	exposed	
to	the	same	Aβo	preparation	but	incubated	in	0	Mg2+/APV-free	solution	during	Aβo	
exposure	(Fig.	6-4C,D).	Thus,	NMDA	receptor	activation	is	required	for	Aβo-induced	
impairment.	So	far,	all	of	our	experiments	were	done	using	spontaneous	quantal	release	to	
activate	NMDA	receptors	in	the	absence	of	Mg2+.	We	also	tested	whether	Aβo	could	still	
impair	NMDA	receptors	in	the	presence	of	physiological	Mg2+	by	allowing	spontaneous	
network	activity	in	the	culture	to	drive	NMDA	receptor	activation	by	excluding	TTX	and	
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adding	1mM	Mg2+	during	Aβo	incubation.	We	observed	a	nearly	identical	decrease	in	QCT	
amplitude	and	a	robust	decrease	in	QCT	frequency	under	these	conditions	(Fig.	6-4E;	
amplitude-PBS:-0.023±0.047,	Aβ+Mg2+:-0.25±0.029,	Aβ:-0.22±0.036;	frequency-
PBS:0.006±0.070,	Aβ+Mg2+:-0.29±0.040,	Aβ:-0.48±0.044).	QCT	frequency	impairment	by	
Aβo	was	slightly	attenuated	compared	to	using	spontaneous	neurotransmission	in	the	
absence	of	Mg2+	to	drive	NMDA	receptor	activation	(Fig.	6-4E),	perhaps	because	a	small	
subset	of	analyzed	synapses	may	not	have	been	sufficiently	activated	by	network	activity	
for	the	Aβo	effect	to	manifest.		
	 Previous	work	has	demonstrated	that	Aβo	synaptotoxicity	is	mediated	through	
NMDA	receptors	containing	the	GluN2B	subunit	78,82,152.	To	determine	whether	this	is	the	
case	for	the	Aβo-mediated	impairment	of	QCTs,	we	tested	whether	the	GluN2B-specific	
antagonist	ifenprodil	occluded	the	effects	of	Aβo.	We	reasoned	that	if	Aβo	was	acting	solely	
through	GluN2B-containing	receptors,	then	blocking	this	subset	of	NMDA	receptors	should	
mask	the	effects	of	Aβo.	We	first	imaged	baseline	QCTs,	then	added	5	μM	ifenprodil	to	the	
bath	solution	and	performed	another	round	of	QCT	imaging.	Ifenprodil	alone	immediately	
caused	a	significant	reduction	in	both	QCT	frequency	and	amplitude	similar	to	that	
observed	following	Aβo	treatment	(Fig.	6-4F),	demonstrating	that	a	significant	fraction	of	
synapses	harbor	GluN2B-containing	NMDA	receptors	in	this	preparation.	We	next	applied	
Aβo	and	incubated	cells	for	an	additional	45	min	and	performed	a	third	round	of	QCT	
imaging	in	the	continued	presence	of	ifenprodil.	Under	these	conditions	we	observed	no	
further	reduction	in	QCT	amplitude	by	Aβo,	and	a	significantly	attenuated	reduction	in	QCT	
frequency	compared	to	Aβo	alone,	supporting	a	major	role	for	GluN2B	in	Aβo-induced	
impairment	(Fig.	6-4G).	One	explanation	for	the	lack	of	complete	occlusion	on	QCT	
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frequency	may	be	due	to	the	presence	of	tri-heteromeric	NMDA	receptors	(containing	both	
GluN2B	and	GluN2A),	which	are	prevalent	in	mammalian	forebrain	neurons	and	are	only	
partially	blocked	by	5	µM	ifenprodil	257,259.	If	Aβo	affects	triheteromeric	receptors,	we	
would	see	a	significant	reduction,	even	in	the	presence	of	ifenprodil.	The	apparent	
complete	occlusion	of	amplitude	by	ifenprodil	may	be	due	to	a	relatively	small	effect	to	
begin	with.		
Distinct	mechanisms	are	responsible	for	Aβo-mediated	QCT	inhibition	and	NMDA	receptor	
internalization	
	 Numerous	previous	studies	have	demonstrated	that	a	fraction	of	GluN2B-containing	
NMDA	receptors	are	endocytosed	following	Aβo	exposure70,142.	We	wanted	to	determine	
whether	NMDA	receptor	internalization	was	responsible	for	the	reduction	in	QCTs	we	
observed.	To	begin	addressing	this	issue,	we	generated	dose	response	curves	measuring	
surface	NMDA	receptors	as	a	function	of	Aβo	concentration	(between	5	pM	and	500	nM)	
under	identical	conditions	to	those	used	for	our	imaging	experiments	(Fig.	6-5).	QCT	
amplitude	and	frequency	were	inhibited	at	extremely	low	doses	of	Aβo,	with	nearly	
identical	IC50	values	(35.02	±	17.93	pM,	amplitude	and	44.67	±	2.42	pM,	frequency)	(Fig.	6-
5A).	Surprisingly,	surface	NMDA	receptor	levels,	measured	using	surface	biotinylation,	
were	not	significantly	reduced	at	Aβo	concentrations	that	fully	saturated	QCT	
amplitude/frequency	reduction	(Fig.	6-5B-D).	We	next	tested	whether	NMDA	receptor	
endocytosis	depended	on	receptor	activation.	Unexpectedly,	unlike	Aβo-mediated	QCT	
impairment,	Aβo-triggered	NMDA	receptor	internalization	was	not	affected	by	APV	(50	µM;	
Fig.	6-5B,	E).	The	drastically	different	dose-response	relationship	and	the	lack	of	use-		
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Figure	6-4.	NMDA	receptor	activity	is	required	for	the	Aβo-induced	decrease	in	QCT	
frequency	and	amplitude.	
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Figure	6-4.	NMDA	receptor	activity	is	required	for	the	Aβo-induced	decrease	in	
QCT	frequency	and	amplitude.	
A.	Traces	from	individual	synapses	before	(red	line)	and	after	(blue	line)	treatment	with	
scrambled	Aβ	(top	example)	or	Aβo	(bottom	three	examples).	Example	of	a	high	
frequency,	low	amplitude	synapse	(Aβo,	top),	a	low	frequency,	high	amplitude	synapse	
(Aβo,	middle)	and	a	low	frequency,	low	amplitude	synapse	(Aβo,	bottom)	are	shown.		
	
B.	Left:	Synapses	were	sorted	based	on	their	initial,	pretreatment	QCT	frequencies.	
Synapses	with	high	initial	frequency	(above	the	mean)	were	more	susceptible	to	Aβo	
than	low	frequency	(below	the	mean)	synapses	(PBS:	less	active:	n=270	spines	from	34	
neurons,	more	active:	n=134	spines	from	34	neurons;	Scr.	Aβ:	less	active:	n=254	spines	
from	36	neurons,	more	active:	n=177	spines	from	36	neurons;	Aβo:	less	active:	n=332	
spines	from	39	neurons,	more	active:	n=135	spines	from	39	neurons;	p=0.0065,	
Student's	t-test)	Right:	Synapses	were	sorted	based	on	their	initial,	pretreatment	QCT	
amplitudes.	Synapses	that	displayed	large	(above	the	mean	value)	baseline	amplitudes	
were	more	susceptible	to	Aβo	than	synapses	with	small	(below	the	mean	value)	
amplitudes.	(PBS:	small	amp:	n=189	spines	from	34	neurons,	large	amp:	n=127	spines	
from	34	neurons;	Scr.	Aβ:	less	active:	n=249	spines	from	36	neurons,	more	active:	n=177	
spines	from	36	neurons;	Aβo:	small	amp:	n=136	spines	from	39	neurons,	large	amp:	
n=82	spines	from	39	neurons;	p<0.0001,	Student's	t-test)			
	
C.	Mg2+	blocks	Aβo-mediated	NMDA	receptor	impairment.	QCTs	were	measured	before	
and	after	45	min	Aβo	incubation	(500	nM)	in	the	presence	of	1mM	Mg2+.	Mg2+	was	
washed	off	immediately	prior	to	post-Aβo	QCT	measurement.	Left:	Effect	of	PBS	plus	
Mg2+	block	(black;	n=275	spines	from	29	neurons),	Aβo	plus	Mg2+	block	(green;	n=358	
spines	from	36	neurons)	and	Aβo	in	nominally	Mg2+-free	ACSF	(blue;	n=121	spines	from	
16	neurons)	on	QCT	amplitude.	Right:	Effect	of	PBS	plus	Mg2+	block	(black;	n=348	spines	
from	29	neurons),	Aβo	plus	Mg2+	block	(green;	n=432	spines	from	36	neurons)	and	Aβo	
in	nominally	Mg2+-free	ACSF	(blue;	n=192	spines	from	16	neurons)	on	QCT	frequency	
(amp	and	freq:	p<0.0001,	Student's	t-test).	
	
D.	APV	blocks	Aβo-mediated	NMDA	receptor	impairment.	QCTs	were	measured	before	
and	after	45	min	Aβo	incubation	in	the	presence	of	50	µM	APV.	APV	was	washed	off	
immediately	prior	to	post-Aβo	QCT	measurement.	Left:	Effect	of	PBS	plus	APV	(black;	
n=216	spines	from	22	neurons),	Aβo	plus	APV	(green;	n=208	spines	from	23	neurons)	
and	Aβo	(blue;	n=125	spines	from	16	neurons)	on	QCT	amplitude.	Right:	Effect	of	PBS	
plus	APV	(black;	n=263	spines	from	22	neurons),	Aβo	plus	APV	(green;	n=276	spines	
from	23	neurons)	and	Aβo	(blue;	n=192	spines	from	16	neurons)	on	QCT	frequency	(amp	
and	freq:	p<0.0001,	Student's	t-test).		
	
E.	Mg2+	does	not	block	Aβo-triggered	reduction	in	QCT	amplitude	(left)	or	frequency	
(right)	if	neurons	are	allowed	to	fire	during	Aβo	exposure.	QCTs	were	measured	before	
and	after	60	min	Aβo	incubation	in	the	presence	of	1	mM	Mg2+,	but	in	the	absence	of	TTX.	
Mg2+	was	removed	and	TTX	was	added	immediately	prior	to	post-Aβo	QCT	measurement.	
Left:	Effect	of	PBS	plus	Mg2+	without	TTX	(black;	n=218	spines	from	22	neurons),	Aβo	
plus	Mg2+	without	TTX	(green;	n=294	spines	from	33	neurons;	p<0.0001)	and	Aβo	from	
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the	same	preparation	without	Mg2+	but	with	TTX	(blue;	n=154	spines	from	18	neurons)	
on	QCT	amplitude.	Right:	Effect	of	PBS	plus	Mg2+	without	TTX	(black;	n=264	spines	from	
22	neurons),	Aβo	plus	Mg2+	without	TTX	(green;	n=395	spines	from	33	neurons;	
p<0.0001	vs.	PBS,	p=0.0029	vs.	Aβo)	and	Aβo	from	the	same	preparation	without	Mg2+	
but	with	TTX	(blue;	n=216	spines	from	18	neurons)	on	QCT	frequency.	
	
F.	Top:	Schematic	of	imaging	paradigm	and	ifenprodil/Aβo	addition.	Bottom:	Effect	of	5	
µM	ifenprodil	on	the	amplitude	and	frequency	of	QCTs	(comparing	imaging	time	2	to	
time	1;	amp:	n=454	spines	from	64	neurons;	freq:	n=792	spines	from	64	neurons).		
	
G.	Effect	of	ifenprodil	on	Aβo-induced	reduction	in	QCT	amplitude	(left)	and	frequency	
(right)	(comparing	imaging	time	3	to	time	2).	Black	bars	represent	the	effect	of	PBS	in	the	
presence	of	ifenprodil	(amp:	n=164	spines	from	34	neurons;	freq:	n=232	spines	from	34	
neurons)	purple	bars	represent	the	effect	of	Aβo	in	the	presence	of	ifenprodil	(amp:	
n=186	spines	from	32	neurons;	freq:	n=330	spines	from	32	neurons)	and	blue	bars	
represent	the	effect	of	the	same	Aβo	preparation	in	the	absence	of	ifenprodil	(amp:	
n=134	spines	from	18	neurons;	p<0.0001;	freq:	n=216	spines	from	18	neurons;	
p=0.0318,	Student's	t-test).		
	 	
	
	 84	
	
Figure	6-5.	Aβo	dose	dependent	reduction	in	QCT	amplitude	and	frequency	
A.	Dose	response	curves	for	QCT	frequency	(solid	blue	line,	left	axis;	0.005	nM,	0.05	nM	
and	0.5	nM	n=144	spines	from	12	neurons,	5	nM	n=132	spines	from	11	neurons,	50	nM	
n=288	spines	from	24	neurons,	500	nM	n=468	spines	from	39	neurons)	and	amplitude	
(dashed	green	line,	right	axis;	0.005	nM	n=117	spines	from	12	neurons,	0.05	nM	n=92	
spines	from	12	neurons,	0.5	nM	n=84	spines	from	12	neurons,	5	nM	n=92	spines	from	11	
neurons,	50	nM	n=178	spines	from	24	neurons,	500	nM	n=218	spines	from	39	neurons).	
	
B.	Representative	western	blot	of	biotinylated	surface	NR1	(top)	and	total	NR1	(bottom).	
A	no	biotin	control	from	a	separate	experiment	is	shown	to	the	right.		
	
C.	Quantification	of	relative	amount	of	surface	NR1/total	NR1	following	treatment	with	
various	concentrations	of	Aβo	normalized	to	PBS	control	treatment.	Data	are	reported	as	
the	mean	from	at	least	3	experiments	using	independent	cultures	and	Aβo	preparations.	
p=0.0004,	one	way	ANOVA,	50	nM	p<0.05,	500	nM	p<0.001,	Tukey’s	Post	Test)	
	
D.	Normalized	(from	0	to	1)	effects	of	Aβo	on	QCT	frequency	(solid	blue	line),	QCT	
amplitude	(dashed	green	line)	and	NMDA	receptor	internalization	(dotted	black	line)	are	
plotted	together	for	direct	comparison.	
	
E.	Left:	Effects	of	Aβo	on	NMDA	receptor	internalization	in	the	absence	(circles)	and	
presence	(squares)	of	APV	normalized	to	PBS	control	treatment.	(see	western	blot	in	B;	
n=3	for	500	nM	Aβo	+	APV;	500	nM	repeated	from	C).	Right:	Effect	of	APV	during	Aβo	
incubation	on	QCT	frequency	and	amplitude	(data	repeated	from	Fig.	5.4D)	
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dependence	indicate	that	impaired	NMDA	receptor	Ca2+	entry	is	occurring	through	a	process	
distinct	from	previously	described	surface	removal	mechanisms.		
Spatial	relationship	between	Aβ	binding	and	NMDA	receptor	function		
	 Given	that	Aβo	only	binds	to	a	subset	of	synapses,	we	wanted	to	ask	whether	it	
recognizes	a	specific	feature	at	these	synapses,	or	whether	it	randomly	associates	non-
specifically	with	cell	membrane.	To	address	this,	we	applied	two	separate	doses	of	Aβo,	
each	labeled	with	a	different	fluorophore.	We	reasoned	that	if	the	first	dose	was	binding	a	
saturable	cell	surface	receptor(s),	it	should	at	least	partially	occlude	subsequent	Aβo	
binding.	On	the	other	hand,	if	the	first	dose	binds	randomly,	we	would	expect	it	not	to	
influence	labeling	with	the	second	dose.	We	first	applied	250	nM	HiLyte	555-labeled	Aβo,	
washed	the	cells	and	then	added	250	nM	HiLyte	647-labeled	Aβo.	We	found	that	labeling	
with	the	first	dose	significantly	reduced	binding	of	the	second	dose	(Figure	6-6A).	
Interestingly,	while	many	spines	that	labeled	with	the	first	dose	had	little	detectable	
labeling	with	the	second,	nearly	all	(92.8%)	the	spines	that	were	labeled	with	the	second	
dose	had	previously	bound	the	first	dose.	Conversely,	synapses	that	did	not	bind	the	first	
dose	were	seldom	positive	for	the	second	dose	(Figure	6-6B).	These	data	are	consistent	
with	a	saturable	surface	receptor	for	Aβo	that	is	expressed	at	some,	but	not	all	excitatory	
synapses.	The	fact	that	we	observed	a	significant	extent	of	co-labeled	surface	puncta	could	
be	the	result	of	previously	described	“seeding	effect”	where	surface	Aβo	clusters	recruit	
additional	Aβo	at	the	site	of	binding	94.	We	next	investigated	the	spatial	relationship	
between	Aβo	surface	binding	and	NMDA	receptor	impairment.	Our	optical	assay	for	NMDA	
receptor	function	can	simultaneously	survey	hundreds	of	synapses	before	and	after	Aβo	
treatment,	allowing	us	to	determine	whether	NMDA	receptor	function	is	equally	
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diminished	at	all	synapses,	or	whether	only	Aβo-bound	synapses	are	affected.	Intriguingly,	
we	observed	reduced	NMDA	receptor	function	at	a	large	fraction	(63.2%	amp;	64.3%	freq)	
of	synapses,	with	a	subset	(36.8%	amp;	35.7%	freq)	of	synapses	resistant	to	Aβo	exposure,	
at	least	over	the	timescale	of	this	experiment.	Previous	work	has	shown	that	soluble	
oligomeric	Aβ	binds	to	a	fraction	(~60%),	but	not	all	excitatory	synapses	74,75,94,	but	it	has	
been	previously	impossible	to	determine	the	relationship	between	Aβo	surface	binding	and	
NMDA	receptor	dysfunction.	To	address	this	issue,	we	used	50	nM	HiLyte	647-labeled	Aβo	
peptide,	which	allowed	us	to	visualize	the	subset	of	synapses	bound	by	Aβ	(63.6±2.5%;	Fig.	
6-6C)	and	simultaneously	assay	NMDA	receptor	function	at	these	synapses,	compared	to	
neighboring	unbound	synapses	on	the	same	dendrites.	We	found	that	both	frequency	and	
amplitude	were	significantly	more	impacted	at	Aβo-positive	spines	compared	to	
neighboring	Aβo-negative	spines	(Fig.	6-6D)	(amp:	Aβo	negative:	0.017±0.081;		Aβo	
positive:	-0.206±0.046,	p=0.012;	freq:	Aβo	negative:	0.085±0.147;	Aβo	positive:	-
0.512±0.057,	p<0.0001,	Student's	t-test),	demonstrating	that	Aβo	acts	locally,	at	the	level	of	
individual	synaptic	sites	to	impair	NMDA	receptor	function.	
	 Since	the	effects	of	Aβo	on	NMDA	receptor	function	require	activation	of	the	
receptor,	we	next	asked	whether	Aβo	preferentially	binds	to	excitatory	synapses	in	an	
activity-dependent	manner.	We	tested	this	by	inactivating	a	subset	of	synaptic	terminals	on	
a	given	postsynaptic	neuron	using	a	lentiviral	vector	expressing	tetanus	toxin	(TeNT)	light	
chain	to	block	neurotransmission	along	with	synaptophysin-GFP	(syph-GFP)	to	label	
silenced	presynaptic	terminals	352	(Fig.	6-6E).	We	infected	dissociated	hippocampal	
cultures	with	a	lentivirus	titer	empirically	determined	to	infect	only	a	fraction	(~50%)	of	
neurons.	Following	1.5-2	weeks	of	expression,	we	added	HiLyte	647-labeled	Aβo,	and	then	
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fixed	and	stained	for	PSD95	to	label	excitatory	synapses.	This	approach	allowed	us	to	
measure	Aβo	at	inactivated	(Syph-GFP	positive)	and	control	(GFP-negative)	excitatory	
synapses.	We	found	no	difference	in	the	level	of	Aβo	binding	at	inactivated	and	neighboring	
control	synapses	(Fig.	6-6E,F).	As	an	independent	measure	of	possible	activity-dependent	
Aβo	binding,	we	also	quantified	Aβo	binding	to	synapses	that	displayed	high	frequency	
(greater	than	the	mean	value)	QCTs	vs.	synapses	with	low	frequency	(lower	than	the	mean	
value)	QCTs	and	observed	no	significant	difference	in	the	amount	of	Aβo	binding	(Fig.	6-
6G).	Thus	Aβo	binding	to	excitatory	synapses	is	not	sensitive	to	synaptic	activity	even	
though	activity	is	required	to	inhibit	NMDA	receptor	Ca2+	entry.	
Discussion	
	 We	used	an	optical	approach	to	assess	the	spatial,	temporal	and	dose	dependent	
effects	of	Aβo	on	synaptic	NMDA	receptor	function.	The	advantage	of	this	approach	is	that	
NMDA	receptor	Ca2+	entry	can	be	visualized	with	high	spatial	resolution	at	hundreds	of	
synapses	before	and	at	various	times	following	experimental	manipulation,	allowing	
longitudinal	comparisons	of	NMDA	receptor	function	at	each	synaptic	site.	This	approach	
complements	and	overcomes	limitations	of	electrophysiological	approaches	not	only	by	
allowing	us	to	resolve	NMDA	receptor	function	at	individual	synapses,	but	also	by	
providing	a	direct	readout	of	Ca2+	influx,	the	central	2nd	messenger	for	NMDA	receptor	
mediated	signaling,	which	is	difficult	to	measure	using	traditional	recording	techniques.	
Coupled	with	imaging	sites	of	Aβo	accumulation,	our	approach	allowed	us	to	investigate	for	
the	first	time	the	relationship	between	synaptic	activity,	Aβo	binding	and	NMDA	receptor	
function.		
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Figure	6-6.	Aβo	binds	to	specific	synapses	and	locally	reduces	QCT	amplitude	and	
frequency	
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Figure	6-6.	Aβo	binds	to	specific	synapses	and	locally	reduces	QCT	amplitude	and	
frequency	
A.	Non-random	binding	of	Aβo.	Cultured	hippocampal	neurons	were	sequentially	
exposed	to	250	nM	Aβo	modified	with	either	HiLyte555	or	HiLyte647	for	fluorescent	
visualization.	Whole	neuron	labeling	with	the	second	Aβo	dose	was	significantly	reduced	
regardless	of	whether	555	or	647-labeled	Aβo	was	applied	first	(555-Aβo	1st	vs	2nd	
p=0.0048;	647-Aβo	1st	vs	2nd	p=0.0008,	Student's	t-test,	n=27	neurons	for	each	
condition).		
	
B.	Aβo	labeling	at	specific	dendritic	spines.	The	image	shows	dendritic	spines	co-labeled	
with	both	doses	of	Aβo	(blue	arrows),	labeled	with	only	the	second	dose	(pink	arrow)	or	
unlabeled	(orange	arrows).	In	the	Venn	diagram	(right),	grey	represents	the	proportion	
of	dendritic	spines	unbound	by	Aβo,	red	represents	the	proportion	of	spines	bound	only	
by	the	first	dose	of	Aβo,	purple	represents	the	proportion	of	spines	bound	only	by	the	
second	dose	of	Aβo,	magenta	represents	the	proportion	of	spines	bound	by	both	the	first	
and	second	doses	(n=26	neurons).	
	
C.	Top:	Representative	image	of	hippocampal	dendrites	expressing	GCaMP6	(green,	
signal	display	gain	is	saturated	so	that	dendritic	spine	morphology	can	easily	be	
identified)	that	were	exposed	to	50	nM	HiLyte	647-labeled	Aβo	for	45	min	prior	to	
imaging	(red).	Bottom:	Zoomed	image	of	Aβo-bound	(blue	arrows)	synapses	and	
neighboring	unbound	(orange	arrows)	synapses	on	the	same	dendritic	branch.		
	
D.	Change	in	amplitude	and	frequency	of	QCTs	at	synapses	with	no	detectable	Aβo	
(black;	amp:	n=72	spines	from	10	neurons;	freq:	n=114	spines	from	10	neurons;)	or	
synapses	with	bound	Aβo	(blue;	amp:	n=94	spines	from	10	neurons;	freq:	n=202	spines	
from	10	neurons;	amp:	p=0.0124;	freq:	p<0.0001,	Student's	t-test).		
	
E.	Left:	Schematic	of	tetanus	toxin	(TeNT)	synapse	inactivation	strategy.	Right:	Segment	
of	dendrite	showing	active	(arrows)	and	inactive	(arrowheads)	synapses	bound	(blue)	
and	unbound	(orange)	by	Aβo.		
	
F.	Left:	Aβo	binds	to	active	and	inactive	synapses.	Matrix	showing	Aβo	binding	to	both	
active	and	inactive	synapses.	Right:	Fluorescence	intensity	of	Aβo	signal	was	normalized	
to	PSD95	signal	at	TeNT	inactived	(n=115	spines	from	11	neurons)	synapses	and	active	
(n=72	spines	from	11	neurons)	synapses.	Scale	bar=1	µm.	
	
G.	Fluorescence	intensity	of	Aβo	binding	at	spines	that	displayed	low	frequency	
spontaneous	activity	(n=367	spines	from	39	neurons)	and	high	frequency	spontaneous	
activity	(n=101	spines	from	39	neurons).	Frequency	was	determined	by	QCT	analysis	at	
each	spine.	
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	 A	surprising	observation	from	our	study	is	that	Aβo-induced	NMDA	receptor	
impairment	is	extremely	heterogeneous,	even	when	comparing	neighboring	synapses	on	
the	same	dendritic	branches.	NMDA	receptor	Ca2+	entry	was	severely	impaired	(such	that	
we	no	longer	observed	QCTs)	at	approximately	53%	of	synapses,	while	12%	of	synapses	
were	completely	resistant	to	Aβo	(no	effect	on	either	QCT	frequency	or	amplitude),	with	
remaining	synapses	showing	a	significant	reduction	in	amplitude	and/or	frequency.	While	
reduced	quantal	amplitude	suggests	a	postsynaptic	reduction	in	the	number	and/or	
function	of	NMDA	receptors,	reduced	quantal	frequency	is	classically	interpreted	as	a	
reduction	in	the	number	of	spontaneous	presynaptic	neurotransmitter	release	events	or	
fewer	synapses	353.	Indeed,	Aβo	has	been	shown	to	reduce	evoked	neurotransmitter	
release	probability	191,354	in	some	studies,	while	reported	to	have	no	effect	in	others	71.	
Under	conditions	of	spontaneous	release,	we	observed	no	change	in	presynaptic	
neurotransmitter	release	as	measured	by	AMPA	receptor	mEPSC	frequency,	in	agreement	
with	previous	reports	183,355.	This	observation,	coupled	with	our	glutamate	uncaging	
experiments,	strongly	suggest	that	reduced	QCT	frequency	arises	from	either	complete	loss	
of	NMDA	receptors	from	a	subset	of	synaptic	sites,	and/or	strongly	impaired	Ca2+	entry	
through	synaptic	receptors,	such	that	NMDA	receptor	activation	can	no	longer	be	detected	
with	fluorescent	Ca2+	indicators.	Previous	studies	using	electrophysiology	to	measure	
synaptic	NMDA	receptor	currents	have	reported	conflicting	effects	of	Aβo	70,78,341.	Our	data	
suggest	that	Aβo	impairs	Ca2+	entry	mediated	by	NMDA	receptors,	but	our	approach	can	
not	be	used	to	determine	how	Aβo	influences	overall	NMDA	receptor	currents	since	Ca2+	
only	contributes	~10%	to	total	conductance	356.	Moreover,	previous	work	has	shown	that	
fractional	Ca2+	conductance	of	NMDA	receptors	can	be	regulated	independent	of	other	
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cations,	suggesting	that	Aβo	could	selectively	impair	Ca2+	entry	with	little	effect	on	total	
receptor	conductance	288,289,357.		
	 What	is	responsible	for	the	heterogenous	effects	of	Aβo	at	different	synaptic	sites?	
Our	approach	is	uniquely	suited	to	address	the	relationship	between	Aβo	binding	and	
synaptic	function.	Consistent	with	previous	reports	74,75,94,	application	of	low	
concentrations	(50	nM	in	our	study)	of	fluorescently	labeled	Aβo	resulted	in	a	punctate	
binding	pattern	that	overlapped	with	a	large	fraction,	but	not	all	excitatory	synapses.	We	
found	that	NMDA	receptor	function	was	much	more	robustly	impaired	at	Aβo-bound	
synapses	vs.	neighboring,	unbound	synapses,	indicating	that	Aβo	binding	to	dendritic	
spines	drives	local	signaling	pathways	that	disrupt	NMDA	receptors	in	a	spatially	restricted	
manner.	Higher	concentrations	(500	nM)	of	Aβo	display	more	widespread	surface	binding	
such	that	the	entire	dendritic	arbor	(and	every	excitatory	synapse)	co-labels	with	Aβo,	yet	
no	further	effect	on	synaptic	NMDA	receptor	Ca2+	influx	was	observed.	Our	dual	labeling	
experiment	shows	that	Aβo	binding	is	not	random	and	suggests	that	a	high	affinity	receptor	
for	Aβo	is	present	at	some,	but	not	all	excitatory	synaptic	sites	and	that	the	more	
widespread	association	observed	at	higher	Aβo	concentrations	is	mediated	by	a	different	
receptor(s).	Numerous	Aβo	receptors	have	been	reported	with	a	broad	range	of	affinities	
spanning	orders	of	magnitude	51,90,94,121.	However,	few	receptors	have	been	described	that	
bind	Aβo	with	high	enough	affinity	to	explain	our	dose-response	relationship,	with	the	
exception	of	the	a7	nicotinic	acetylcholine	receptor,	which	is	reported	to	bind	Aβo	with	low	
picomolar	affinity	51.		
	 Synaptic	activity	and	neural	firing	is	reported	to	accelerate	processing	and	release	of	
Aβ	peptide,	but	whether	Aβ	preferentially	binds	to	synapses,	or	selectively	impairs	NMDA	
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receptors	in	an	activity-dependent	manner	has	been	difficult	to	address	76,77,358.	We	
observed	that	synapses	displaying	either	more	frequent	or	larger	amplitude	spontaneous	
Ca2+	transients	were	more	susceptible	to	Aβo-induced	NMDA	receptor	impairment.	This	
suggests	either	use-dependent	synapse	binding	and/or	a	use-dependent	mode	of	
impairment.	Using	a	synapse-specific	inactivation	strategy,	we	demonstrate	that	Aβo	
surface	binding	is	not	influenced	by	synaptic	activity,	but	that	subsequent	NMDA	receptor	
impairment	requires	NMDA	receptor	activation.	Thus,	local	Aβo	binding	with	subsequent	
NMDA	receptor	activation	are	both	required	for	the	effect.	
	 While	the	molecular	signaling	mechanisms	mediating	Aβo-triggered	impairment	of	
NMDA	receptor	Ca2+	entry	await	further	experiments,	numerous	previous	studies	have	
shown	potent	regulation	of	NMDA	receptor	trafficking	and	function	through	
posttranslational	modifications	of	the	GluN2B	subunit	278,288,289,359-361.	Consistent	with	this,	
we	observed	nearly	complete	occlusion	of	Aβo	effects	when	we	specifically	inhibited	
GluN2B-containing	NMDA	receptors.	The	most	likely	mechanism	that	could	explain	our	
results	is	Aβo-triggered	NMDA	receptor	endocytosis	mediated	by	dephosphorylation	of	
Tyr1472	by	striatal-enriched	protein	tyrosine	phosphatase	70,142.	Indeed,	our	biochemical	
data	agree	with	previous	reports	demonstrating	that	Aβo	causes	robust	NMDA	receptor	
internalization	70,142.	However,	we	believe	the	Aβo-triggered	reduction	in	NMDA	receptor	
Ca2+	entry	we	observe	occurs	through	a	distinct	mechanism	for	two	reasons.	First,	Aβo-
mediated	effects	on	QCT	amplitude	and	frequency	saturate	at	a	much	lower	Aβo	
concentration	than	that	required	for	NMDA	receptor	internalization.	Second,	even	at	high	
Aβo	doses	(500	nM),	Aβo-mediated	QCT	impairment	was	use-dependent,	while	Aβo-
triggered	receptor	internalization	was	not.	This	latter	observation	suggests	that	Aβo	
	
	 93	
triggers	internalization	of	predominantly	extrasynaptic	receptors	since	synaptic	QCTs	were	
unperturbed	under	these	conditions,	even	though	total	surface	NMDA	receptors	were	
reduced	by	nearly	50%.	If	NMDA	receptor	function	is	not	impaired	through	endocytosis,	
then	what	could	be	the	mechanism?	NMDA	receptor	regulation	by	
phosphorylation/dephosphorylation	at	other	sites	on	GluN2B	has	been	the	topic	of	intense	
interest.	Phosphorylation	sites	for	CaMKII,	casein	kinase	2,	DAPK1	and	PKA	have	been	
identified	on	the	GluN2B	C-terminal	tail	that	impact	synaptic	localization	and	channel	
properties	278,288,289,359-361.	For	example,	recent	experiments	have	demonstrated	that	NMDA	
receptor	Ca2+	permeability	can	be	regulated	by	PKA	phosphorylation	at	Ser1166	289.	Thus,	
it	is	possible	that	Aβo	selectively	impairs	NMDA	receptor	Ca2+	entry	with	little	effect	on	
overall	NMDA	receptor	current.	Such	a	mechanism	could	explain	discrepancies	between	
our	study	and	previous	experiments	showing	little	to	no	change	in	total	NMDA	receptor	
currents	following	Aβo	exposure	since	Ca2+	contributes	only	modestly	to	total	NMDA	
receptor	current	70,341.	Alternatively,	posttranslational	modifications	could	dissociate	
NMDA	receptors	from	synaptic	sites	without	reducing	total	surface	receptor	levels.	Future	
investigation	will	focus	on	whether	Aβo-triggered	QCT	reduction	is	a	result	of	loss	of	
synaptic	NMDA	receptors	and/or	a	reduction	in	Ca2+	permeability.	The	simplicity	of	our	
assay	will	allow	rapid	pharmacological	and	genetic	dissection	of	the	receptor	and	signaling	
mechanisms	linking	Aβo	to	NMDA	receptor	impairment.	
	 Together,	our	data	support	a	model	where	Aβo	engages	a	high	affinity	surface	
receptor	through	an	interaction	that	does	not	depend	on	synaptic	activity.	Aβo	engagement	
leads	to	use-dependent	and	local	impairment	of	synaptic	NMDA	receptor	Ca2+	influx	
distinct	from	previously	described	surface	trafficking	mechanisms.	More	broadly,	we	
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introduce	a	simple,	robust,	high-resolution	optical	assay	for	NMDA	receptor	function	at	
individual	synaptic	sites	that	will	be	a	powerful	platform	for	investigating	the	
spatiotemporal	dynamics	of	NMDA	receptor	signaling	for	synaptic	function	in	health	and	
disease.		
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CHAPTER	VII	
CONCLUSIONS	AND	FUTURE	DIRECTIONS	
Perspective	
	 Understanding	the	function	of	Ab	both	normally	and	pathophysiologically	is	
essential	for	developing	new	treatments	for	AD.	If	we	know	the	receptor(s)	and	
downstream	targets	of	Ab,	we	may	have	a	better	chance	of	developing	drugs	that	actually	
work	to	combat	the	effects	of	Ab	on	synaptic	function.	Although	we	will	likely	never	be	able	
to	fully	restore	lost	synaptic	connections,	early	detection	of	AD	and	effective	treatments	
will	allow	us	to	halt	progression	of	the	disease	during	its	mildest	stages.	Additionally,	
individuals	with	known	familial	mutations	could	begin	treatment	before	developing	
symptoms,	potentially	curing	or	at	least	significantly	slowing	progression	of	the	disease.		
	 Learning	and	memory	deficits	in	AD	mouse	models	or	slices	treated	with	Ab	have	
been	one	of	the	foundational	and	highly	repeatable	results	in	the	AD	field	as	a	whole.	
Extensive	work	has	focused	on	characterizing	pathways	that	reverse	the	effects	of	Ab	on	
LTP	and,	to	a	lesser	extent,	spine	loss	and	behavioral	memory	deficits.	These	gross	
characterizations	of	the	effects	of	Ab	have	provided	a	wealth	of	insight	into	the	overall	
changes	in	AD	and	provide	evidence	for	Ab	as	one	of	the	key	pathological	agents	in	AD,	but	
a	significant	lag	in	more	basic	molecular	studies	remains.	Very	basic	questions,	such	as	the	
identity	of	the	receptor	for	Ab	or	whether	Ab	binds	to	pre-	vs.	post-synaptic	terminals,	
remain	unresolved.	This	thesis	was	aimed	at	understanding	one	potential	pathological	
effect	of	Ab-how	it	affects	an	essential	receptor	for	learning	and	memory,	the	NMDAR.		
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Summary	of	Findings	
	 Prior	to	this	work,	the	effect	of	Ab	on	NMDARs	remained	unclear.	Several	studies	
suggested	that	NMDARs	are	activated	by	Ab343-345,	resulting	in	disrupted	Ca2+	homeostasis;	
however,	NMDARs	are	also	required	for	LTP,	suggesting	that	they	may	be	inhibited	by	Ab.	
Using	the	genetically	encoded	Ca2+	indicator	GCaMP6,	I	monitored	Ca2+	flux	through	
NMDARs	following	spontaneous	vesicle	release	and	found	that	NMDAR	Ca2+	flux	is	reduced.	
This	reduction	requires	NMDAR	activation	and	occurs	locally	at	synapses	bound	by	Ab.	
Surprisingly,	this	reduction	in	NMDAR	Ca2+	flux	does	not	appear	to	be	caused	by	loss	of	
NMDARs	from	synapses,	even	though	we	and	others	have	seen	a	~50%	reduction	in	
surface	NMDARs	following	treatment	with	Ab1,70,132.	
	 The	next	obvious	question	is	whether	Ab	is	binding	directly	to	NMDARs	to	reduce	
their	function.	Super	resolution	imaging	of	Ab	relative	to	pre	and	postsynaptic	markers,	
NMDARs	and	AMPARs	suggests	the	Ab	is	not	binding	to	NMDARs	but	is	binding	to	
excitatory	synapses	peripheral	to	PSD95	(excitatory	synapses),	but	not	gephyrin	
(inhibitory	synapses).	Further	analysis	of	this	data	will	reveal	specifics	about	Ab	binding	
and	its	relationship	to	synaptic	markers.	This	approach	may	help	narrow	down	the	
candidates	for	Ab	receptors.	Unfortunately,	antibodies	tested	against	prion	protein,	PirB	
and	mGluR5	displayed	a	high	level	of	background	labeling	and	additional	troubleshooting	
of	these	antibodies	or	others	could	show	more	definitively	whether	Ab	binds	to	these	
proposed	receptors. 
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Future	Directions	
Mechanism	of	NMDAR	dysfunction	
	 In	order	to	determine	which	signaling	pathways	are	involved	in	NMDAR	
dysfunction,	we	must	first	understand	exactly	what	is	happening	to	NMDARs.	Are	the	
NMDARs	moving	out	of	the	synapse?	Is	their	localization	changed	so	they	cannot	respond	
as	efficiently	to	glutamate?	We	already	know	from	our	studies	and	others	that	GluN2B-
containing	NMDARs	are	specifically	involved	in	Ab-induced	synapse	dysfunction1,70,81,	so	
we	wondered	whether	there	were	any	changes	in	NMDAR	subunit	composition	or	specific	
function	of	GluN2B-containing	NMDARs.	In	order	to	begin	assessing	how	NMDARs	were	
affected,	I	performed	glutamate	uncaging	while	recording	electrical	and	Ca2+	responses	
(Figure	7-1a).	I	found	that	while	the	Ca2+	response	following	uncaging	was	significantly	
reduced	in	cells	treated	with	Ab,	the	total	current	was	not	affected	(Figure	7-1).	We	must	
perform	additional	experiments	to	confirm	the	source	of	this	Ca2+	decrease	since	the	
reduced	Ca2+	response	could	result	from	decreased	Ca2+-induced	Ca2+	release	from	internal	
stores	or	increased	Ca2+	transport	out	of	the	neurons.	
Assuming	reduced	NMDAR	influx	is	the	cause	of	reduced	spine	Ca2+,	this	result	
suggests	that	NMDARs	are	being	altered	to	decrease	their	Ca2+	conductance	without	
influencing	overall	current.	Previous	studies	indicate	that	phosphorylation	of	the	GluN2B	
C-terminal	tail	at	S1166	can	alter	the	Ca2+	conductance	of	NMDARs	without	affecting	
overall	current288,289,357.	This	phosphorylation	is	regulated	by	PKA,	but	the	counterpart	
phosphatase	remains	unidentified.	Additional	work	must	be	done	to	determine	whether	
this	phosphorylation	event	is	altered	in	the	presence	of	Ab.		
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The	lack	of	change	in	total	NMDAR	current	does	not	rule	out	the	possibility	that	
NMDARs	are	also	changing	their	localization	within	synapses-this	must	be	tested	with	
super	resolution	microscopy,	such	as	PALM/STORM,	since	glutamate	uncaging	experiments	
bathe	the	entire	spine	head	with	glutamate	rather	than	the	restricted	release	of	glutamate	
from	single	vesicles.	Additionally,	Y1472	on	the	C-terminal	tail	of	GluN2B	is	
dephosphorylated	in	the	presence	of	Ab	by	STEP61,	resulting	in	the	removal	of	NMDARs	
from	the	membrane70,142.	Experiments	expressing	chimeric	GluN2B	subunits	whose	tails	
have	been	exchanged	for	those	of	GluN2A	will	help	determine	whether	the	effect	of	Ab	is	
mediated	through	the	C-terminal	tail	of	GluN2B.	Whether	the	phosphorylation	state	of	
GluN2B	changes	in	the	presence	of	Ab	could	be	determined	with	radioactive	labeling	and	
further	analysis	of	target	sites	within	the	C-tail	of	GluN2B	could	be	assessed	through	
mutagenesis.					
Signaling	pathways	associated	with	Ab-induced	NMDAR	dysfunction	
As	discussed	in	Chapter	II,	an	overwhelming	number	of	receptors	and	signaling	
pathways	have	been	implicated	in	the	blockade	of	LTP	following	Ab	application.	Super	
resolution	imaging	of	proposed	Ab	receptors	may	also	help	narrow	the	search	for	
receptors/signaling	pathways	involved	in	synapse	dysfunction.	The	antibodies	for	many	of	
these	targets	are	generally	non-specific,	so	use	of	CRISPR	based	genome	editing	tools,	such	
as	homology-independent	universal	genome	editing	(HiUGE,	Soderling	Lab),	to	introduce	a	
fluorescent	protein	or	epitope	tag	on	the	endogenous	protein	may	provide	high	quality	
labeling	of	proteins	for	super	resolution	imaging.	Top	candidates	without	quality	
antibodies,	such	as	mGluR5,	PirB	and	prion	protein	could	be	investigated	in	this	way.		
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Figure	7-1.	Ca2+	imaging	and	recording	combined	with	uncaging	reveals	a	unique	
effect	of	Ab	on	NMDAR	Ca2+	flux	
A.		Example	image	of	a	neuron	expressing	GCaMP3.	ROIs	indicate	spines	that	were	
activated	by	glutamate	uncaging.		
B.	Top:	Ca2+	traces	from	individual	spines	following	uncaging.	Bottom:	NMDAR	currents	
from	individual	spines	following	uncaging.	Colors	match	ROIs	in	A.	
C.	Left:	uEPSCs	measured	from	cells	incubated	with	PBS	(black)	or	Ab	(blue)	for	at	least	45	
mins.	Middle:	Ca2+	flux	following	uncaging	from	cells	incubated	with	PBS	(black)	or	Ab	
(blue)	for	at	least	45	mins.	Right:	Uncaging	evoked	Ca2+	influx	(GCaMP3	fluorescence)	
divided	by	the	uEPSC	at	individual	spines	from	cells	incubated	with	PBS	(black)	or	Ab	
(blue)	for	at	least	45	mins.	
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In	addition	to	determining	the	receptor	for	Ab	via	super	resolution	imaging,	we	also	
wanted	to	test	which	pathways	may	be	involved	in	the	reduction	in	NMDAR	function	
following	Ab	treatment.	Since	NMDARs	are	central	to	LTP,	we	wondered	whether	any	of	the	
signaling	pathways	involved	in	LTP	blockade	are	also	involved	in	the	reduction	in	NMDAR	
Ca2+	flux.	Preliminary	data	indicates	that	blocking	PKA	mimics	the	effects	of	Ab	on	NMDAR	
function	and	occludes	any	further	effects	of	Ab	(Figure	7-2).	Interestingly,	CaN	blockade	did	
not	affect	the	Ab-induced	reduction	in	NMDAR	function	(Figure	7-2)	even	though	blocking	
CaN	blocks	spine	loss	and	rescues	LTP.	This	suggests	that	CaN	activation	is	downstream	of	
reduced	NMDAR	function.	
	 Additional	signaling	molecules,	especially	other	phosphatases	such	as	PP1	and	
PP2A,	should	be	investigated	to	determine	which	phosphatase	activity	is	leading	to	the	
reduction	in	NMDAR	function.	Further,	determining	whether	PKA	activity	is	reduced	by	Ab	
will	be	important	to	test.	Finally,	additional	potential	signaling	pathways,	such	as	mGluR5	
could	also	be	tested	pharmacologically.		
Endogenous	function	of	Ab	?	
	 During	the	course	of	this	work	there	was	one	result	we	found	particularly	
surprising-that	NMDAR	dysfunction	occurs	at	picomolar	doses	of	Ab.	This	result	suggested	
to	us	that	the	ability	of	Ab	to	decrease	NMDAR	Ca2+	flux	may	in	fact	play	a	role	
physiologically.	Spine	loss	and	blockade	of	LTP	require	nanomolar	doses	of	Ab,	suggesting	
that	the	effects	of	Ab	at	very	low	concentrations	might	have	effects	seen	in	healthy	brains.	
Ab	is	released	from	neurons	following	high	levels	of	activity76,	which	would	allow	Ab	to	
subsequently	provide	a	brake	for	NMDAR	Ca2+	flux,	especially	in	immature	brains	where	
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GluN2B	is	the	dominant	subunit.	This	may	protect	neurons	from	excitotoxicity	since	
GluN2B-containing	NMDARs	conduct	significantly	more	Ca2+	than	GluN2A-containing	
NMDARs,	whose	expression	increases	throughout	development.		
	 In	addition	to	stimulating	exocytosis	of	Ab,	high	levels	of	activity	also	trigger	the	
switch	from	GluN2B	to	GluN2A-containing	NMDARs.	It	would	be	interesting	to	test	whether	
APP	knockout	mice	have	improper	NMDAR	subunit	switching	during	development	using	
electrophysiology	and	pharmacology	to	isolate	GluN2B	vs.	GluN2A-specific	NMDAR	
currents	at	different	developmental	time	points.	Since	the	physiological	role	of	APP	
remains	understudied,	it	would	also	be	important	to	test	whether	this	was	an	Ab	specific	
effect	by	using	APP	mutant	mice	that	cannot	produce	Ab,	but	still	produce	the	other	APP	
cleavage	products,	which	are	likely	important	for	other	cellular	functions.		
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Figure	7-2.	Signaling	molecules	involved	in	Ab-induced	NMDAR	dysfunction	
A.	Cells	were	imaged	at	baseline	(time	1),	following	10	min	of	300	nM	PKI	(time	2)	and	
following	45	min	of	Ab	+	PKI	(time	3).	PKI	alone	(time	1/time	2)	results	in	a	decrease	in	
decreased	amplitude	and	frequency	of	QCTs.	Addition	of	Ab	(time	3/time	2)	has	no	
additional	effect	(right).	
B.	Uncaging	induced	NMDAR	Ca2+	influx	is	reduced	in	the	presence	of	Ab	(blue)	and	is	
similarly	affected	in	the	presence	of	cyclosporin	A	(pink)	using	high	(500	nM-left)	and	low	
(500	pM-right)	concentrations	of	Ab.	
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